Introduction
============

Due to shared routes of transmission, chronic hepatitis C virus (HCV) is prevalent among HIV-infected populations \[[@R1]\]. It is estimated that as many as 4.4 million people are co-infected globally, with the highest prevalence (\>80%) observed among HIV-infected people who inject drugs \[[@R2]\]. Compared with HCV mono-infection, HIV co-infected patients have lower spontaneous clearance rates, higher HCV viral loads, and accelerated progression of HCV-associated liver disease \[[@R3],[@R4]\]. In the era of combination antiretroviral therapy (cART), rates of liver-related outcomes, including cirrhosis and hepatocellular carcinoma are increased in the setting of HCV--HIV co-infection, contributing to excess mortality in this population \[[@R5],[@R6]\].

With increasing life expectancy, chronic kidney disease (CKD) has emerged as an important cause of morbidity in the HIV-infected population \[[@R7]\]. Without timely identification, HIV-infected individuals with CKD are at increased risk of cardiovascular disease and premature mortality \[[@R8],[@R9]\]. Although the cause of CKD in HIV-infected patients on cART is likely multifactorial, and includes exposure to nephrotoxic antiretroviral agents \[[@R10]\], greater prevalence of traditional CKD risk factors \[[@R11]\], immunosuppression \[[@R12]\], and host/genetic factors \[[@R13]\], HCV co-infection has been identified as a leading risk factor for CKD and end-stage renal disease (ESRD) in this population \[[@R14]--[@R16]\]. These observations support the current view of chronic HCV as a systemic illness that is associated with extrahepatic comorbidities in both the general and HIV-infected population \[[@R17],[@R18]\]. Recent evidence has suggested an association between illicit drug use and CKD, though separating the effect of viral replication and substance use has been difficult \[[@R19]--[@R21]\].

The benefits of successful HCV treatment in HCV--HIV co-infected individuals include both a reduction in all-cause and liver-related mortality and improvement in quality of life \[[@R22],[@R23]\]. There has, however, been comparatively less research on the role of viral cure on extrahepatic chronic illness, including CKD. There is evidence suggesting a possible protective effect from interferon-based treatment on incident CKD/ESRD in HCV mono-infected populations in Asia \[[@R24],[@R25]\]. These studies have been limited by small numbers of clinical events, lack of laboratory confirmation of a sustained virologic response (SVR) to treatment, and lack of adjustment for potential confounders, such as substance use and other risk behaviours. As such, the findings may not be generalizable to HIV-infected populations in North America and Europe. Furthermore, there is currently no data evaluating risk factors for CKD progression among co-infected patients who achieve SVR, a population who will become more numerous as new direct-acting antivirals (DAAs) are rolled-out.

We sought to determine whether SVR reduces short-term rates of kidney function decline in HCV--HIV co-infected Canadians and to evaluate the contributions of ongoing illicit cocaine and opiate use on kidney function decline among co-infected patients who achieved SVR.

Patients and methods
====================

Canadian Co-Infection Cohort
----------------------------

Data were obtained from the Canadian Co-Infection Cohort (CCC), a large multicentre prospective study, which has enrolled HCV--HIV co-infected patients from 18 hospital and community-based clinics across Canada. The cohort has been described previously \[[@R26]\]. Briefly, all participants complete a baseline questionnaire to provide demographic and risk factor information and study coordinators collect information on HIV and HCV treatment histories and clinical comorbidities. Questionnaire and clinical data is updated biannually. The study was approved by the community advisory committee of the Canadian Institutes of Health Research -- Canadian HIV Trials Network and by all institutional ethics boards of participating centres. Written informed consent was obtained for all patients.

Inclusion criteria
------------------

We included all co-infected patients with chronic HCV who were enrolled between January 2003 and December 2016. Patients were excluded if they had evidence of spontaneous HCV clearance or had previously achieved an SVR prior to enrollment.

Study design
------------

To examine the association between SVR and kidney function, we employed a longitudinal cohort study design with incidence-density sampling. We created a base cohort with all chronically infected patients and defined a risk set on each calendar date a patient achieved an SVR (the index date). Each risk set contained chronic HCV patients who had a study visit +/−30 days of the index date. Patients who would eventually develop SVR were eligible to be included in control risk sets for other SVR patients before they initiated therapy. Patients who developed SVR were excluded from all exposure risk sets and patients who failed HCV treatment during the study period remained classified as chronically infected.

Definitions
-----------

SVR was defined by either an undetectable qualitative polymerase chain reaction (e.g. Amplicor HCV Test v2.0) or quantitative (e.g. Abbott Real Time HCV) HCV viral load below the assay\'s lower limit of detection, obtained at least 12 weeks after the end of HCV treatment. Estimated glomerular filtration rates (eGFR) were calculated using the serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@R27]\]. Alcohol consumption and illicit (injection and noninjection) cocaine and opiate substance use was obtained by self-report at each visit. Hazardous alcohol consumption was assessed using the Alcohol Use Disorders Identification Test (AUDIT-C) score \[[@R28]\]. Duration of HCV infection was estimated as the earliest date of starting to use injection drugs or date of first positive serologic test. Hypertension was defined by clinical diagnosis or two consecutive visits with SBP at least 140 mmHg or DBP at least 90 mmHg. Diabetes was defined by clinical diagnosis or two consecutive visits with either fasting serum glucose at least 7 mmol/l or random serum glucose at least 11.1 mmol/l. Liver fibrosis was measured using the aspartate aminotransferase-to-platelet ratio index (APRI) with values at least 1.5 indicative of significant fibrosis (≥ F2) \[[@R29]\].

Statistical analysis
--------------------

SVR patients were matched with chronically infected patients using time-dependent propensity scores \[[@R30]\]. Conditional logistic regression was used to calculate the probability of developing SVR given time-varying patient characteristics at each risk set defined on the index date \[[@R31]\]. We matched patients on the logit of the propensity score using the nearest neighbor algorithm to select two chronically infected patients. Matching was performed with replacement and no caliper was used. The use of time-dependent propensity score matching ensures that patients who developed SVR during the interferon-based and interferon-free eras were matched with comparable patients who could have been treated during the same time period but were ultimately not. The propensity score model included potential confounders of the SVR and CKD relationship and independent predictors of kidney function \[[@R32]\]. Covariates included age, sex, aboriginal and African/Caribbean ethnicity, injection and noninjection cocaine and opiate use in the last 6 months, hazardous alcohol use, CD4^+^ T-cell count (linear and quadratic term), detectable HIV RNA (≥ 50 copies/ml), current or previous tenofovir disoproxil fumarate or protease inhibitor use, duration of HCV infection, hypertension, diabetes, significant liver fibrosis, and baseline eGFR. Balance of covariate distributions was assessed by comparing standardized mean differences \[[@R33]\]. For all patients in the matched sample, analysis follow-up time began on the index date and person-time was censored at the earliest of death, last available kidney function measurement, HCV treatment initiation (if a matched patient would develop SVR), or 31 December 2016.

In our primary analysis, we used a population-averaged linear model fit with generalized estimating equations (GEE) to compare annual rates of eGFR decline between SVR and chronically infected patients \[[@R34]\]. The difference in eGFR slopes between the two groups was measured with an interaction term between exposure status and linear time in three separate models. First, we fit an 'unadjusted' model, which only accounts for differences in measured baseline characteristics in our propensity score-matched sample. Second, we accounted for residual imbalances in baseline characteristics by including both linear and quadratic terms for the propensity score in the GEE model. Lastly, we included time-updated covariates to estimate the direct effect of SVR on eGFR that is not mediated by changing values of other variables that may be modified by SVR status. We assumed an exchangeable correlation structure and robust standard errors were used to account for repeated longitudinal data and the matching with replacement.

In our secondary analysis, we examined the association between illicit drug use and annual rates of kidney function decline among HIV-infected patients who achieved SVR using a similar population-averaged linear model. Differences in eGFR slopes, adjusted for age, sex, ethnicity, CD4^+^ T-cell count, detectable HIV viral load, HCV duration and liver fibrosis, were estimated with an interaction term between each drug and linear time. Short-term kidney function trajectories between those who used injection or noninjection cocaine and opiates, as compared with nonusers, were estimated in a reference 50-year-old, male, Caucasian HIV-infected patient who achieved SVR and was infected with HCV for 20 years, had no liver fibrosis, an undetectable HIV viral load, and a CD4^+^ T-cell count at least 500 cells/μl. Statistical analyses were performed using STATA version 14.1 (College Station, Texas, USA).

Results
=======

Of the 1726 co-infected patients who were enrolled in the CCC since 2003, we excluded 42 spontaneous clearers and 53 patients who were previously treated and developed SVR (Supplemental Figure). Characteristics of the base cohort at enrollment, as well as those with spontaneous clearance and previous SVR are shown in Supplemental Table 1. During the study period, 562 patients were treated for chronic HCV. Of those treated, a treatment response was not available for 53 patients (9%), most of whom had just recently completed therapy (42/53; 79%). Of the 509 patients with known treatment responses, 45 (9%) had not yet completed any posttreatment study follow-up. Of the 457 patients with an available treatment result and posttreatment follow-up, 384 (84%) developed SVR.

Measured baseline covariate balance between patients who achieved SVR (*n* = 384) and propensity score-matched chronically infected patients (*n* = 768) are shown in Table [1](#T1){ref-type="table"}. Covariates appeared balanced between the two populations, with no substantial imbalances between the two study groups. More than half of all patients in the SVR group were treated with an all-oral DAA regimen (202/384; 53%) and 70% had HCV genotype 1 (268/384).

###### 

Comparison of baseline characteristics in the propensity score-matched sample.

                                                                          Sustained virologic response (*n* = 384)   Chronic infection (*n* = 768)   Standardized mean difference
  ----------------------------------------------------------------------- ------------------------------------------ ------------------------------- ------------------------------
  Median age (IQR) (years)                                                51 (45--55)                                51 (45--55)                     0
  Female                                                                  80 (21%)                                   169 (22%)                       0.03
  African/Caribbean ethnicity                                             17 (4%)                                    24 (3%)                         0.07
  Aboriginal ethnicity                                                    35 (9%)                                    75 (10%)                        0.02
  Injection cocaine use                                                   43 (11%)                                   94 (12%)                        0.03
  Injection opiate use                                                    46 (12%)                                   90 (12%)                        0.01
  Noninjection cocaine use                                                61 (16%)                                   142 (18%)                       0.07
  Noninjection opiate use                                                 58 (15%)                                   128 (17%)                       0.04
  Hazardous alcohol consumption                                           64 (17%)                                   141 (18%)                       0.04
  Median current CD4^+^ count (IQR) (cells/μl)                            530 (360--740)                             530 (330--760)                  0.01
  Median nadir CD4^+^ count (IQR) (cells/μl)                              190 (90--300)                              190 (90--325)                   0.09
  Detectable HIV RNA at least 50 copies/ml                                39 (10%)                                   72 (9%)                         0.03
  Prior AIDS-defining events                                              98 (26%)                                   226 (29%)                       0.09
  Current tenofovir disoproxil fumarate exposure                          223 (58%)                                  430 (56%)                       0.04
  Ever tenofovir disoproxil fumarate exposure                             267 (70%)                                  533 (69%)                       0
  Current protease inhibitor exposure[^a^](#TF1-1){ref-type="table-fn"}   112 (29%)                                  216 (28%)                       0.02
  Ever protease inhibitor exposure[^a^](#TF1-1){ref-type="table-fn"}      178 (46%)                                  354 (46%)                       0.01
  Median duration of HCV infection (IQR) (years)                          21 (12--30)                                21 (12--29)                     0.02
  Hypertension                                                            57 (15%)                                   119 (15%)                       0.02
  Diabetes                                                                28 (7%)                                    50 (7%)                         0.03
  Liver fibrosis (APRI ≥ 1.5)                                             156 (41%)                                  348 (45%)                       0.09
  Median eGFR (IQR) (ml/min per 1.73 m^2^)                                91 (74--104)                               91 (74--104)                    0.01
  Recent hospitalization in the last 6 months                             41 (11%)                                   100 (13%)                       0.07

Values are *n* (%), unless otherwise indicated. APRI, aspartate aminotransferase-to-platelet ratio index; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; IQR, interquartile range.

^a^Lopinavir/ritonavir or atazanavir, with or without ritonavir.

In the primary analysis, we included 1152 HCV--HIV co-infected participants who were followed for a total of 1767 person-years of follow-up (PYFU). A total of 4041 post-SVR eGFR measurements were available for analysis. The mean follow-up time was 1.6 years in the SVR group and 1.5 years in the chronically infected group. Annual rates of decline in eGFR were similar between SVR \[−1.32 (ml/min per 1.73 m^2^)/year, 95% confidence interval (CI) −1.75 to −0.90\] and chronically infected patients \[−1.19 (ml/min per 1.73 m^2^)/year, 95% CI −1.55 to −0.84; Table [2](#T2){ref-type="table"}\]. Our results were similar after additionally adjusting for the propensity score to account for measured baseline covariate imbalances. After including time-dependent covariates in the outcome model, rates of eGFR decline were slightly attenuated, though there remained no statistically or clinically significant difference between the two groups.

###### 

Annual rates of eGFR decline \[(ml/min per 1.73 m^2^)/year\] between sustained virologic response and chronic hepatitis C virus patients in the propensity score-matched sample (*n* = 1152).

                ΔeGFR \[(ml/min per 1.73 m^2^)/year; 95% CI\][^a^](#TF2-1){ref-type="table-fn"}                            
  ------------- --------------------------------------------------------------------------------- ------------------------ ------------------------
  SVR           −1.32 (−1.75 to −0.90)                                                            −1.41 (−1.72 to −1.11)   −1.26 (−1.70 to −0.83)
  Chronic HCV   −1.19 (−1.55 to −0.84)                                                            −1.28 (−1.53 to −1.02)   −1.16 (−1.54 to −0.79)
  Difference    −0.13 (−0.68 to 0.42)                                                             −0.14 (−0.54 to 0.26)    −0.10 (−0.67 to 0.47)

CI, confidence interval; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; SVR, sustained virologic response.

^a^Robust standard errors.

^b^Unadjusted propensity score-matched sample.

^c^Propensity score-matched sample with additional adjustment for propensity score using linear and quadratic term.

^d^Propensity score-matched sample with additional adjustment for time-updated covariates: injection and noninjection drug use, hazardous alcohol consumption, CD4^+^ cell count, detectable HIV RNA, current use of tenofovir disoproxil fumarate, current use of atazanavir or lopinavir, hypertension, diabetes, and liver fibrosis.

Among the 384 patients who achieved SVR, 43 (11%) and 46 (12%) patients reported recent injection cocaine and injection opiate use within the last 6 months, respectively, and 61 (16%) and 58 (15%) reported recent noninjection crack/cocaine and opiate use, respectively. After SVR, the adjusted annual rate of change in eGFR was faster among active injection cocaine users \[−2.16 (ml/min per 1.73 m^2^)/year, 95% CI −4.17 to −0.16\], as compared with nonusers of any illicit drug \[−0.67 (ml/min per 1.73 m^2^)/year, 95% CI −1.14 to −0.20\] but was not statistically significant \[difference: −1.49 (ml/min per 1.73 m^2^)/year, 95% CI −3.49 to 0.51\]. No similar accentuation in decline was observed among the other illicit drugs (Supplemental Table 2). Analyses of eGFR trajectories demonstrated that in the reference population, after 5 years, injection cocaine users will have a lower eGFR (76 ml/min per 1.73 m^2^, 95% CI 68--83), compared with nonusers of any illicit drug (86 ml/min per 1.73 m^2^, 95% CI 84--88). There were no significant differences in eGFR trajectories between other illicit drug users and nonusers (Fig. [1](#F1){ref-type="fig"}).

![Kidney function trajectories in the reference population, by illicit drug use, among patients with sustained virologic response (*n* = 384).](aids-32-751-g001){#F1}

Discussion
==========

In this analysis of HCV--HIV co-infected patients who were treated in both the interferon and interferon-free eras, we found that annual rates of change in eGFR were similar between those who were successfully treated and comparably matched patients who were chronically infected. These findings suggest that there is no immediate benefit of successful HCV treatment for kidney function and that HCV cure may not reduce the overall incidence of CKD in co-infected patients.

Our results differ from previous reports in cohort studies of HIV-negative populations. In a clinical cohort of 650 HCV mono-infected patients with cirrhosis treated with interferon in Japan, SVR was associated with a 63% reduction in CKD incidence \[[@R24]\]. Given this population was cirrhotic, this finding may be explained by the impact of SVR on liver disease progression, which reduces the risk of hepatorenal syndrome, and not specifically an effect of HCV elimination on renal function \[[@R35]\]. A large administrative-linked, population-based study in Taiwan reported that initiation of HCV treatment was associated with an 85% decline in ESRD incidence compared with untreated HCV-infected individuals \[[@R25],[@R36]\]. This study excluded patients with advanced liver disease and specific comorbidities, such as those with psychiatric diagnoses, which would be a contraindication to interferon-based treatment and did not control for lifestyle risk factors, such as alcohol and drug use, which would be less common in people who initiate therapy with interferon. The protective association of interferon treatment may, therefore, be overestimated, though because of the large effect, further investigation is warranted.

Our findings, however, are consistent with two recent cohort studies examining the association between HCV viral eradication and CKD in co-infected populations treated in the interferon era. In an analysis of 340 HCV--HIV co-infected patients treated in Italy, Leone *et al.*\[[@R37]\] report that achieving a SVR was not associated with a shorter time to incident CKD. Similarly, an analysis of 2503 co-infected patients in the Swiss HIV Cohort Study found no evidence that successful treatment with interferon was associated with a reduced risk of ESRD, as compared with those who were chronically infected \[[@R38]\]. In contrast, a recent Spanish cohort study, which directly compared 1625 HCV--HIV co-infected patients with SVR to those who failed treatment in the interferon-era, reported a clinically significant protective effect of SVR on CKD \[[@R39]\]. The latter study, however, did not adjust for baseline eGFR and if low eGFR is an important predictor for failing to achieve SVR, then the non-SVR group would have shorter time to CKD and the protective effect of successful treatment may be overestimated \[[@R24]\].

HCV has been implicated as an important risk factor for metabolic, cardiovascular, kidney, and neurological extrahepatic manifestations \[[@R17],[@R40]\]. Although the pathophysiologic effect of HCV on extrahepatic comorbidities are not completely understood, they are likely related to a combination of direct HCV effects, such as viral replication in extrahepatic cells, or immune activation resulting in chronic inflammation, and indirect effects such as drug and alcohol use, poor nutrition, and HIV-related issues \[[@R23]\]. For some comorbidities, such as diabetes, wherever HCV viral replication is known to directly affect insulin-signaling pathways\[[@R17]\], the effect of successful treatment has resulted in a reduction of clinical outcomes observed in several epidemiologic studies \[[@R38],[@R39],[@R41]\]. For other extrahepatic comorbidities, such as cardiovascular disease and CKD, the mechanisms are likely multifaceted and HCV viral eradication alone may not reduce the incidence of all clinical outcomes. For example, on the one hand, chronic HCV has been associated with favourable lipid profiles \[[@R42]\], but has also been associated with greater prevalence of atherogenic risk factors \[[@R43]\]. In epidemiologic studies, SVR has been strongly associated with a significant reduction in cerebrovascular events and acute coronary syndrome in a HCV mono-infected population \[[@R25],[@R44]\], but produced conflicting results in HIV co-infected populations \[[@R38],[@R39]\]. For kidney diseases, it is clear that HCV treatment reduces complications associated with mixed cryoglobulinemia, which is associated with the development of membranoproliferative glomerular nephritis (MPGN) disease, though it is less clear if HCV treatment has an impact on kidney function in patients without any underlying renal diseases \[[@R45]\].

There are several factors that may explain our null findings. First, given that most co-infected patients have been infected with HCV for more than two decades, it is possible that successful HCV treatment may have a limited impact on the kidney after HCV replication has continued unabated during this long period. This is unlikely, however, as most patients had normal kidney function (≥90 ml/min per 1.73 m^2^) at the time of SVR, suggesting that HCV itself may not be an important contributor to CKD in HIV-infected populations and that other exposures such as cocaine use may explain the increased risk of chronic renal impairment \[[@R20]\]. Second, it may be possible that SVR may have a stronger effect on kidney function among subpopulations of patients who are more likely to rapidly progress to ESRD after developing CKD, such as HIV-infected African Americans, who carry the *APOL1* or *MYH9* genetic variants, or patients with cirrhosis or diabetes \[[@R46]\]. We were underpowered, however, to test this hypothesis in our study.

Few studies have examined the relative contributions of HCV viremia, lifestyle factors, and alternative mechanisms to the development of CKD in patients with chronic viral infections \[[@R19]--[@R21]\]. We reported earlier that frequent and cumulative exposure to injection crack/cocaine was associated with chronic renal impairment in HCV--HIV co-infected patients, independent of HCV viral replication \[[@R20]\]. Garg *et al.*\[[@R19]\] have also reported an association between crack/cocaine use and acute kidney injury among a small cohort of chronic HCV-infected patients. Recently, in a large cohort of HCV mono-infected veterans and matched controls, Rogal *et al.*\[[@R21]\] found that both alcohol and drug dependence, as measured with administrative billing codes, were associated with an increased risk of CKD. We extend these findings to HIV co-infected patients who achieved SVR and note the increasing role that substance use, namely injection cocaine, has on short-term kidney function. Whether these effects persist after long-term substance use or whether kidney function normalizes after cessation remains to be investigated. This is the first study to examine the effect that lifestyle risk factors have on kidney function after SVR, and we encourage the development of further long-term studies assessing the impact of substance use on CKD and other extrahepatic illnesses in HIV or HCV-infected populations \[[@R23]\].

Our analysis adds to the developing body of literature on extrahepatic outcomes following successful HCV treatment in the co-infected population and has several strengths. First, we included a large number of patients who were treated with DAAs, which have replaced interferon-based therapy for both treatment-naive and treatment-experienced chronic HCV patients, regardless of genotype. Compared with previous research in this area, our study population is, then, more generalizable to those co-infected patients initiating care in low-incidence settings. Second, our use of time-dependent propensity scores reduces the impact that unmeasured confounding, which varies with time would have on influencing both why patients would initiate HCV treatment and subsequent changes in their kidney function. This is particularly important, as our research encompasses several distinct HCV treatment periods, with an increasing number of HCV--HIV co-infected patients with comorbid conditions initiating treatment. Lastly, our use of routinely measured eGFR values allows us to model annual rates of change in kidney function, which are clinically relevant for those treating HIV-infected patients on stable antiretroviral therapy. Furthermore, the use of repeated eGFR measurements allow us to increase statistical power, as compared with previous analyses, and reduce biases associated with irregular eGFR measurements leading to CKD diagnosis in patients at risk for the outcome.

Our study has several potential limitations. First, we were limited by a relatively short follow-up, particularly among those who were recently treated with new DAA regimens. Therefore, we had insufficient follow-up time to allow incident CKD events to occur. Second, we could not directly compare SVR patients with patients who failed treatment, given the small numbers of co-infected patients who failed (*n* = 73). Comparison of these two groups would provide a less biased estimate of the effect of SVR on kidney function, as it would control for factors related to treatment initiation, but such analyses have become increasingly difficult as HCV treatment becomes much more effective. Our method of using time-dependent propensity scores with incidence density sampling provided a matched sample with comparable baseline characteristics. It is possible, however, that unmeasured characteristics, such as poor nutrition or the use of concomitant nephrotoxic medications, may have been more prevalent in the chronically infected group and these factors may also have influenced eGFR \[[@R47]\] however, the groups were well balanced with respect to HIV disease stage, comorbid conditions, and recent hospitalizations suggesting exposure to such medications would likewise be balanced. Furthermore, we were unable to assess if urinary biomarkers of kidney disease, such as proteinuria, were differentially distributed between our study groups. Lastly, we relied on patient self-report to assess illicit drug-use exposures. Although this may be affected by social desirability biases, nurses and clinicians maintain good relationships with study participants in the CCC, yielding little incentive to falsely reporting data.

In conclusion, we found that SVR was not associated with a short-term reduction in the rate of change in eGFR among HCV--HIV co-infected patients receiving clinical care. Regardless, HCV treatment should continue to be promoted, given its clear benefits in reducing the risk of liver-disease progression, premature mortality, and HCV transmission. For co-infected individuals who achieved SVR, monitoring eGFR in those who continue to use cocaine and referral to substance-use services would be beneficial, given their higher risk of experiencing kidney injury over time.
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